Costs and margins
BRIEF: For the nine months ended 30 September 2014, Enzon Pharmaceuticals Inc revenues decreased 8% to $24.9M. Net income increased 81% to $23M. Revenues reflect Royalties decrease of 6% to $24.8M, Miscellaneous income decrease of 85% to $93K. Net income reflects General and administrative decrease of 75% to $1.9M (expense), Restructuring charges decrease from $3.8M (expense) to $0K.
* From 1 January 2015, if your stockbroking account is accessible under the same login as your spread betting or CFD account, you can automatically qualify for our lowest commission rate by placing at least one spread bet or CFD trade in the previous calendar month. See our full charges and fees.